Walleye Trading’s Health Catalyst HCAT Stock Holding History

Walleye Trading’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,570	Closed	-$254K	–	5403
2021 Q2	$254K	Buy	+4,570	New	+$243K	﹤0.01%	3685

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Walleye Trading's HCAT Position: Q3 2021 in Review

Walleye Trading sold out of Health Catalyst (HCAT) in Q3 2021, closing a stake of 4,570 shares — an estimated $254K sold.

Walleye Trading first reported a position in HCAT in Q2 2021 and held it in 1 quarter. The position peaked at $254K in Q2 2021. 198 funds tracked by Wall St. Rank hold HCAT as of Q3 2021.

Walleye Trading reported no remaining Health Catalyst position as of Q3 2021 after selling out during the quarter.
Walleye Trading sold 4,570 Health Catalyst shares in Q3 2021, an estimated $254K.
Walleye Trading first reported a position in Health Catalyst in Q2 2021 and held it in 1 quarter.
Walleye Trading's Health Catalyst position peaked at $254K in Q2 2021.
198 funds tracked by Wall St. Rank held Health Catalyst as of Q3 2021.

Based on Walleye Trading's 13F filing for Q3 2021, filed 15 Nov 2021.